Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists for Obesity Management
JAMA Network Open · 25.10.2024 · 7 (10) · e2441380
DOI: 10.1001/jamanetworkopen.2024.41380 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 25.10.2024. Verfasst von Kevin Lin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This cross-sectional study investigates rates of bariatric surgery and glucagon-like peptide-1 receptor agonist prescription among adults without diabetes in 2022 to 2023.
Autor:innen und Institutionen
- Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
- Department of Health Services, Policy and Practice, Brown School of Public Health, Providence, Rhode Island.
- Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
Zitieren
APA
Lin, K., Mehrotra, A., & Tsai, T. C. (2024). Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists for Obesity Management. JAMA Network Open, 7(10), e2441380. https://doi.org/10.1001/jamanetworkopen.2024.41380
Vancouver
Lin K, Mehrotra A, Tsai TC. Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists for Obesity Management. JAMA Network Open. 2024;7(10):e2441380. doi:10.1001/jamanetworkopen.2024.41380
BibTeX
@article{Lin2024,
author = {Lin, Kevin and Mehrotra, Ateev and Tsai, Thomas C},
title = {Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists for Obesity Management},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {10},
pages = {e2441380},
doi = {10.1001/jamanetworkopen.2024.41380}
}
EUVIMED